Interleukin-12 - Ichor Medical Systems

Drug Profile

Interleukin-12 - Ichor Medical Systems

Alternative Names: IL-12/TriGrid™ - Ichor Medical Systems

Latest Information Update: 22 Jun 2005

Price : $50

At a glance

  • Originator Ichor Medical Systems
  • Class Adjuvants; Interleukins
  • Mechanism of Action Immunostimulants; Interleukin 12 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 22 Jun 2005 This compound is still in active development for Cancer
  • 15 Sep 2003 Preclinical trials in Cancer in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top